China Sky One Medical, Inc. Successfully Develops Semi-Quantitative Automatic
Inspection Device for Diagnostic Kits
HARBIN, China, May 4 /Xinhua-PRNewswire-FirstCall/ -- China Sky One
Medical, Inc. ("China Sky One Medical" or "the Company")
(OTC Bulletin Board: CSKI), a leading fully integrated pharmaceutical company
for external use, over-the-counter drugs in the People's Republic of China
("PRC"), today announced the successful development of a semi-quantitative
automatic inspection device for its diagnostic kits.
Harbin First Bio-Engineering Company Limited ("First"), a wholly-owned
subsidiary of China Sky One Medical, has developed a series of diagnostic kits
under the support of the Chinese government which significantly improve the
accuracy of early cancer detection. In order to interpret the results from
these diagnostic kits, physicians must use advanced equipment. This has
impeded broader adoption of the diagnostic kits as very few hospitals in China
are equipped with this type of equipment. As a result, the Company
collaborated with Harbin Institute of Technology Machinery and Automation
College to develop a semi-quantitative automatic inspection system for its
diagnostic kits to aid physicians in interpreting the results.
The new inspection system utilizes transferred photoelectron technology.
By attaching the inspection device to a diagnostic kit, the physician is able
to easily determine the test results without utilizing other equipment. By
simplifying the diagnostic process, the new device should stimulate faster
adoption of the Company's diagnostic kits by healthcare professionals. The
device has been examined by experts in the field and has been submitted to the
SDFA for approval. China Sky One Medical is responsible for all the research
expenses and holds the patent for the device.
"We are excited about the development of our semi-quantitative automatic
inspection device," said Mr. Yan-Qing Liu, Chairman and CEO of China Sky One
Medical, Inc. "We believe that by combining our kits with the inspection
device, it will promote wider adoption of the kits by healthcare professionals
and make a meaningful contribution to our revenue in the future. The unique
sales model of bundling diagnostic kits with the inspection device will help
to maintain profits and increase our competitiveness going forward."
About China Sky One Medical, Inc.
China Sky One Medical, Inc., a Nevada corporation, is a holding company.
The Company engages in the manufacturing, marketing and distribution of
pharmaceutical, medicinal and diagnostic products. Through its wholly-owned
subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company
("TDR")
and Harbin First Bio- Engineering Company Limited ("First"), the Company
manufactures and distributes over-the-counter pharmaceutical products, which
make up its major revenue source. For more information, visit
http://www.skyonemedical.com .
Safe Harbor Statement
Certain of the statements made in the press release constitute forward-
looking statements within the meaning of the Private Securities Litigation
Reform Act of 1995. These statements can be identified by the use of forward-
looking terminology such as "believe," "expect," "may," "will," "should,"
"project," "plan," "seek," "intend," or "anticipate" or the negative thereof
or comparable terminology. Such statements typically involve risks and
uncertainties and may include financial projections or information regarding
our future plans, objectives or performance. Actual results could differ
materially from the expectations reflected in such forward-looking statements
as a result of a variety of factors, including the risks associated with the
effect of changing economic conditions in The People's Republic of China,
variations in cash flow, reliance on collaborative retail partners and on new
product development, variations in new product development, risks associated
with rapid technological change, and the potential of introduced or undetected
flaws and defects in products, and other risk factors detailed in reports
filed with the Securities and Exchange Commission from time to time.
For more information, please contact:
China Sky One Medical, Inc.
Ms. Xiaoyan Han, CFO
Tel: +86-1335-999-3681
Email: tdrhan@163.com
CCG Elite Investor Relations Inc.
Mr. Crocker Coulson, President
Tel: +1-646-213-1915 (New York)
Email: crocker.coulson@ccgir.com
SOURCE China Sky One Medical, Inc.
Ms. Xiaoyan Han, CFO of China Sky One Medical, Inc., +86-1335- 999-3681, or
tdrhan@163.com; Or Mr. Crocker Coulson, President of CCG Elite Investor
Relations Inc., +1-646-213-1915 (New York), or crocker.coulson@ccgir.com
